Last week, a US District Court blocked federal prosecutors from continuing a case against a medical marijuana cultivation company as a result of the current, albeit limited, congressional protections from the Department of Justice.
Year: 2017
The Medical Marijuana Research Act of 2017 amends the federal law to facilitate clinical investigations involving the use of cannabis and cannabis-derived products.
Washington State Governor Jay Inslee and Attorney General Bob Ferguson responded to a July 24 letter from US Attorney General Jeff Sessions, in which Sessions’ made multiple allegations all based on a single misleading 2016 report.
One of NORML’s primary missions is to move public opinion sufficiently to legalize the responsible use of marijuana by adults. One of the ways we successfully achieve this goal is by debunking marijuana myths and half-truths via the publication of timely op-eds in online and print media.
At the Georgia Republican Assembly Convention on 8/12/2017 David Baker, the Executive Director of the Faith and Freedom Coalition of Georgia, used a portion of a 1993 quote from the then Executive Director of NORML, Richard Cowan.
This bill prohibits state-sanctioned marijuana consumers and businesses from being prosecuted by the federal government.
NORML’s 2017 Conference at the Capitol Hilton in Washington, DC and Congressional Lobby Day at the United States Capitol is scheduled for September 10th-12th. Hundreds of marijuana consumers, activists, patients and business owners are expected to attend a day-long training and informational conference on Monday and re-convene on The Hill Tuesday to personally lobby their elected members of the House of Representatives and Senate.
Trauma patients who test positive for marijuana upon their admission to the intensive care unit are less likely to die during hospitalization than are age-matched controls, according to data published online ahead of print in The Journal of Trauma and Acute Care Surgery. Researchers concluded: “Patients with a positive marijuana screen had a lower mortality rate (5.3 percent versus 8.9 percent) compared to patients with a negative marijuana screen.”